Resistant Hypertension Optimal Treatment Trial: A Randomized Controlled Trial

Imagem de Miniatura
Arquivos
art_KRIEGER_Resistant_Hypertension_Optimal_Treatment_Trial_A_Randomized_Controlled_2014.PDF (180.02 KB)
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
BARRETO-FILHO, Jose Augusto Soares
NOGUEIRA, Armando da Rocha
MILL, Jose Geraldo
Citação
CLINICAL CARDIOLOGY, v.37, n.1, p.1-6, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The prevalence of resistant hypertension (ReHy) is not well established. Furthermore, diuretics, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and calcium channel blockers are largely used as the first 3-drug combinations for treating ReHy. However, the fourth drug to be added to the triple regimen is still controversial and guided by empirical choices. We sought (1) to determine the prevalence of ReHy in patients with stage II hypertension; (2) to compare the effects of spironolactone vs clonidine, when added to the triple regimen; and (3) to evaluate the role of measuring sympathetic and renin-angiotensin-aldosterone activities in predicting blood pressure response to spironolactone or clonidine. The Resistant Hypertension Optimal Treatment (ReHOT) study (ClinicalTrials.gov NCT01643434) is a prospective, multicenter, randomized trial comprising 26 sites in Brazil. In step 1, 2000 patients will be treated according to hypertension guidelines for 12 weeks, to detect the prevalence of ReHy. Medical therapy adherence will be checked by pill count monitoring. In step 2, patients with confirmed ReHy will be randomized to an open label 3-month treatment with spironolactone (titrating dose, 12.5-50 mg once daily) or clonidine (titrating dose, 0.1-0.3 mg twice daily). The primary endpoint is the effective control of blood pressure after a 12-week randomized period of treatment. The ReHOT study will disseminate results about the prevalence of ReHy in stage II hypertension and the comparison of spironolactone vs clonidine for blood pressure control in patients with ReHy under 3-drug standard regimen.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/5339
Referências
  1. Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
  2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002, JAMA-J AM MED ASSOC, V288, P2981
  3. Appel LJ, 2008, CIRCULATION, V118, P214, DOI 10.1161/CIRCULATIONAHA.108.788497
  4. Berecek KH, 2004, CURR HYPERTENS REP, V6, P211, DOI 10.1007/s11906-004-0071-z
  5. Bobrie G, 2012, J HYPERTENS, V30, P1656, DOI 10.1097/HJH.0b013e3283551e98
  6. Butler RN, 1997, JAMA-J AM MED ASSOC, V278, P1372, DOI 10.1001/jama.278.16.1372
  7. Calhoun DA, 2008, HYPERTENSION, V51, P1403, DOI 10.1161/HYPERTENSIONAHA.108.189141
  8. Carl D, 2007, CURR HYPERTENS REP, V9, P297, DOI 10.1007/s11906-007-0054-y
  9. Chapman N, 2007, HYPERTENSION, V49, P839, DOI 10.1161/01.HYP.0000259805.18468.8c
  10. Che Q, 2009, CLEV CLIN J MED, V76, P533, DOI 10.3949/ccjm.76a.09030
  11. Daugherty SL, 2012, CIRCULATION, V125, P1635, DOI 10.1161/CIRCULATIONAHA.111.068064
  12. de la Sierra A, 2011, HYPERTENSION, V57, P898, DOI 10.1161/HYPERTENSIONAHA.110.168948
  13. Drager LF, 2010, PLOS ONE, V5
  14. Drager LF, 2010, AM J CARDIOL, V105, P1135, DOI 10.1016/j.amjcard.2009.12.017
  15. Egan BM, 2011, CIRCULATION, V124, P1046, DOI 10.1161/CIRCULATIONAHA.111.030189
  16. Feldman RD, 2009, HYPERTENSION, V53, P646, DOI 10.1161/HYPERTENSIONAHA.108.123455
  17. Howard B. V., 2002, CIRCULATION, V105, P132, DOI 10.1161/01
  18. Krumholz HM, 2002, J AM COLL CARDIOL, V40, P603, DOI 10.1016/S0735-1097(02)02083-1
  19. LARAGH JH, 1979, JAMA-J AM MED ASSOC, V241, P151, DOI 10.1001/jama.241.2.151
  20. LIAO DP, 1995, AM J CARDIOL, V76, P906, DOI 10.1016/S0002-9149(99)80260-4
  21. Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3
  22. Maciel R M, 1981, Arq Bras Cardiol, V36 Suppl 1, P47
  23. Mancia G, 2012, J HYPERTENS, V30, P1514, DOI 10.1097/HJH.0b013e3283567338
  24. Netzer NC, 1999, ANN INTERN MED, V131, P485
  25. Pedrosa RP, 2011, HYPERTENSION, V58, P811, DOI 10.1161/HYPERTENSIONAHA.111.179788
  26. Persell SD, 2011, HYPERTENSION, V57, P1076, DOI 10.1161/HYPERTENSIONAHA.111.170308
  27. Pimenta E, 2008, HYPERTENSION, V51, P339, DOI 10.1161/HYPERTENSIONAHA.107.100701
  28. Pimenta E, 2012, CIRCULATION, V125, P1594, DOI 10.1161/CIRCULATIONAHA.112.097345
  29. Sociedade Brasileira de Cardiologia-SBC/Sociedade Brasileira de HipertensAo-SBH/Sociedade Brasileira de Nefrologia-SBN, 2007, ARQ BRAS CARDIOL, V89, pe24
  30. Taler SJ, 2002, HYPERTENSION, V39, P982, DOI 10.1161/01.HYP.0000016176.16042.2F
  31. Vaclavik J, 2011, HYPERTENSION, V57, P1069, DOI 10.1161/HYPERTENSIONAHA.111.169961
  32. Viera AJ, 2009, AM FAM PHYSICIAN, V79, P863
  33. ZWEIFLER A, 1977, AM J CARDIOL, V40, P105, DOI 10.1016/0002-9149(77)90108-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - LIM/13